A Multicenter, Open-label, Randomized Controlled Phase II Clinical Study of Ribociclib Combined with Aromatase Inhibitors (AI) Versus Chemotherapy Followed by Physician's Choice of Endocrine Therapy in Elderly Patients with Node-positive, Intermediate-to-high Risk HR+/HER2- Early Breast Cancer. (ChiCTR) - Oct 16, 2026 - P2 | N=620 | Not yet recruiting | Sponsor: The Second Affiliated Hospital of Dalian Medical University; The Second Affiliated Hospital of Dalian Medical University
New P2 trial • Breast Cancer • HER2 Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2
|